(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Rezolute's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast RZLT's revenue for 2027 to be $282,906,868, with the lowest RZLT revenue forecast at $0, and the highest RZLT revenue forecast at $2,329,600,364. On average, 9 Wall Street analysts forecast RZLT's revenue for 2028 to be $6,492,028,956, with the lowest RZLT revenue forecast at $955,412,508, and the highest RZLT revenue forecast at $18,831,891,174.
In 2029, RZLT is forecast to generate $18,828,039,480 in revenue, with the lowest revenue forecast at $3,773,214,990 and the highest revenue forecast at $52,753,753,538.